Artiva BiotherapeuticsARTV +8.95%12 Market Cap is $467.42 Mil as of Jun. 28, 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,429 Biotechnology companies, Artiva Biotherapeutics ranks better than 70.33% on this metric.
Artiva Biotherapeutics's quarterly market cap
increased
from Sep. 2025 ($70.44 Mil) to Dec. 2025 ($105.52 Mil) and
increased
from Dec. 2025 ($105.52 Mil) to Mar. 2026 ($159.18 Mil).
Artiva Biotherapeutics's annual market cap
increased
from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($244.86 Mil) but then
declined
from Dec. 2024 ($244.86 Mil) to Dec. 2025 ($105.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Artiva Biotherapeutics's Enterprise Value for Today is $390.90 Mil.
Artiva Biotherapeutics (NAS:ARTV) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artiva Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artiva Biotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Artiva Biotherapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Artiva Biotherapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artiva Biotherapeutics (ARTV) has a Market Cap of $467.42 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Artiva Biotherapeutics and its competitors. According to the industry distribution chart, Artiva Biotherapeutics ranks #424 out of 1429 companies in the Biotechnology industry, placing it in the top 29.7%.
Is Artiva Biotherapeutics' Market Cap too high?
Artiva Biotherapeutics' current Market Cap is $467.42 Mil. The Biotechnology industry median Market Cap is 112.70. Artiva Biotherapeutics' value of $467.42 Mil is 314.8% above this industry median. Based on the distribution chart, Artiva Biotherapeutics ranks #424 out of 1429 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' Market Cap compare to ENTA and VNDA?
According to the Biotechnology industry distribution chart, Artiva Biotherapeutics ranks #424 out of 1429 companies for Market Cap. This puts Artiva Biotherapeutics in the upper half of its industry. The industry median Market Cap is 112.70. Artiva Biotherapeutics' value of $467.42 Mil is 314.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artiva Biotherapeutics's current Market Cap of $467.42 Mil is 314.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Artiva Biotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artiva Biotherapeutics's current Market Cap is $467.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current Market Cap of $467.42 Mil. The current Market Cap is $467.42 Mil and 314.8% above the Biotechnology industry median of 112.70. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current Market Cap is $467.42 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score
Get the complete analysis for ARTV
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTV has been successfully added to your 
